Anabela Cardoso

1 month ago | dermatologytimes.com | Kaitlyn Bader |Anabela Cardoso

“With lebrikizumab, in addition to showing fast initial relief of each and skin, which we showed at 16 weeks, we now looked at the patients who achieved that, and what are the outcomes after 3 years.

1 month ago | dermatologytimes.com | Kaitlyn Bader |Anabela Cardoso

“This study we presented here for the first time is just dedicated to adolescents. It is the largest study of a JAK inhibitor dedicated to adolescents with severe alopecia areata,” said Anabela Cardoso, MD, in an interview at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.